Risk of Hypertension in Cancer Patients Treated with Aflibercept: A Systematic Review and Meta-Analysis
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risk of Hypertension in Cancer Patients Treated with Aflibercept: A Systematic Review and Meta-Analysis
Authors
Keywords
Bevacizumab, Sunitinib, Pazopanib, Aflibercept, Axitinib
Journal
CLINICAL DRUG INVESTIGATION
Volume 34, Issue 4, Pages 231-240
Publisher
Springer Nature
Online
2014-02-03
DOI
10.1007/s40261-014-0174-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials
- (2013) W.-X. Qi et al. ANNALS OF ONCOLOGY
- Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis
- (2013) Wei-Xiang Qi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Aflibercept
- (2013) K. K. Ciombor et al. CLINICAL CANCER RESEARCH
- Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
- (2013) Philippe Rougier et al. EUROPEAN JOURNAL OF CANCER
- The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis
- (2013) Alyssa Fischer et al. INVESTIGATIONAL NEW DRUGS
- Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis
- (2013) T Funakoshi et al. JOURNAL OF HUMAN HYPERTENSION
- Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
- (2013) Ian F Tannock et al. LANCET ONCOLOGY
- Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials
- (2012) Wei-Xiang Qi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis
- (2012) Wei-Xiang Qi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A preclinical and clinical review of aflibercept for the management of cancer
- (2012) Andrew Gaya et al. CANCER TREATMENT REVIEWS
- Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer
- (2012) P. A. Tang et al. CLINICAL CANCER RESEARCH
- Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration
- (2012) Ciro Costagliola et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study
- (2012) Robert L. Coleman et al. GYNECOLOGIC ONCOLOGY
- Risk of venous thromboembolic events associated with VEGFR-TKIs: A systematic review and meta-analysis
- (2012) Wei-Xiang Qi et al. INTERNATIONAL JOURNAL OF CANCER
- Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial
- (2012) Rodryg Ramlau et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin
- (2011) A. A. Tarhini et al. CLINICAL CANCER RESEARCH
- A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia
- (2011) H.J. Mackay et al. GYNECOLOGIC ONCOLOGY
- A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites
- (2011) Nicoletta Colombo et al. GYNECOLOGIC ONCOLOGY
- Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
- (2011) John F. de Groot et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
- (2011) B. I. Rini et al. JNCI-Journal of the National Cancer Institute
- Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study
- (2011) Walter H Gotlieb et al. LANCET ONCOLOGY
- Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
- (2011) Olivier Keunen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis
- (2010) V. Ranpura et al. AMERICAN JOURNAL OF HYPERTENSION
- A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung
- (2010) Natasha B. Leighl et al. Journal of Thoracic Oncology
- Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis
- (2010) Sanjaykumar Hapani et al. ONCOLOGY
- Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial
- (2010) Przemyslaw Twardowski et al. UROLOGY
- Aflibercept in epithelial ovarian carcinoma
- (2009) John W Moroney et al. Future Oncology
- Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
- (2009) Sanjaykumar Hapani et al. LANCET ONCOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
- (2008) Xiaolei Zhu et al. ACTA ONCOLOGICA
- Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients
- (2008) Shobha Rani Nalluri et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
- (2008) Shenhong Wu et al. LANCET ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started